Rockefeller Capital Management
BSX icon

Rockefeller Capital Management’s Boston Scientific BSX Stock Holding History

Rockefeller Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8M Buy
721,186
+9,245
+1% +$502K 0.05% 355
2026
Q1 		$44.7M Buy
711,941
+116,003
+19% +$9.28M 0.08% 243
2025
Q4 		$56.8M Buy
595,938
+247,097
+71% +$24.2M 0.1% 188
2025
Q3 		$34.1M Buy
348,841
+123,185
+55% +$12.8M 0.07% 270
2025
Q2 		$24.2M Buy
225,656
+54,573
+32% +$5.52M 0.05% 331
2025
Q1 		$17.3M Buy
171,083
+23,009
+16% +$2.32M 0.04% 408
2024
Q4 		$13.2M Buy
148,074
+10,110
+7% +$890K 0.03% 465
2024
Q3 		$11.5M Buy
137,964
+13,268
+11% +$1.05M 0.03% 506
2024
Q2 		$9.59M Buy
124,696
+29,132
+30% +$2.13M 0.03% 525
2024
Q1 		$6.55M Buy
95,564
+40,377
+73% +$2.6M 0.02% 620
2023
Q4 		$3.19M Buy
55,187
+5,931
+12% +$317K 0.01% 768
2023
Q3 		$2.6M Sell
49,256
-52,243
-51% -$2.74M 0.01% 757
2023
Q2 		$5.49M Buy
101,499
+37,088
+58% +$1.94M 0.02% 572
2023
Q1 		$3.22M Buy
64,411
+19,480
+43% +$918K 0.01% 670
2022
Q4 		$2.08M Buy
44,931
+3,673
+9% +$159K 0.01% 737
2022
Q3 		$1.6M Buy
41,258
+4,094
+11% +$164K 0.01% 839
2022
Q2 		$1.38M Buy
37,164
+5,394
+17% +$220K 0.01% 882
2022
Q1 		$1.41M Buy
31,770
+6,022
+23% +$261K 0.01% 937
2021
Q4 		$1.09M Sell
25,748
-21,281
-45% -$894K 0.01% 1022
2021
Q3 		$2.04M Buy
47,029
+12,069
+35% +$534K 0.01% 741
2021
Q2 		$1.49M Buy
34,960
+3,244
+10% +$136K 0.01% 795
2021
Q1 		$1.23M Buy
31,716
+3,395
+12% +$128K 0.01% 723
2020
Q4 		$1.02M Buy
28,321
+7,596
+37% +$274K 0.01% 684
2020
Q3 		$791K Buy
20,725
+8,664
+72% +$334K 0.01% 660
2020
Q2 		$423K Buy
12,061
+9,528
+376% +$343K ﹤0.01% 762
2020
Q1 		$83K Buy
2,533
+1,180
+87% +$46.1K ﹤0.01% 1072
2019
Q4 		$61K Buy
1,353
+361
+36% +$15.1K ﹤0.01% 1099
2019
Q3 		$40K Buy
992
+640
+182% +$27.1K ﹤0.01% 1031
2019
Q2 		$15K Sell
352
-1,678
-83% -$64.5K ﹤0.01% 1092
2019
Q1 		$78K Buy
+2,030
New +$77.5K ﹤0.01% 816

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Rockefeller Capital Management's BSX Position: Q2 2026 in Review

Rockefeller Capital Management increased its Boston Scientific (BSX) stake by 1.3% in Q2 2026, buying an estimated $502K and bringing the position to 721,186 shares worth $30.8M. The position accounts for 0.05% of the portfolio, ranked #355.

Rockefeller Capital Management first reported a position in BSX in Q1 2019 and has held it in 30 quarters since. The position peaked at $56.8M in Q4 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Rockefeller Capital Management held 721,186 shares of Boston Scientific worth $30.8M as of Q2 2026.
  • Rockefeller Capital Management bought 9,245 Boston Scientific shares in Q2 2026, an estimated $502K.
  • Boston Scientific made up 0.05% of Rockefeller Capital Management's portfolio in Q2 2026, its #355 holding.
  • Rockefeller Capital Management first reported a position in Boston Scientific in Q1 2019 and has held it in 30 quarters since.
  • Rockefeller Capital Management's Boston Scientific position peaked at $56.8M in Q4 2025.
  • 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.